Resona Asset Management Co. Ltd. Sells 15,983 Shares of Boston Scientific Corporation $BSX

Resona Asset Management Co. Ltd. lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 3.4% during the fourth quarter, Holdings Channel reports. The fund owned 454,945 shares of the medical equipment provider’s stock after selling 15,983 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Boston Scientific were worth $43,411,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB boosted its stake in shares of Boston Scientific by 5.1% in the 4th quarter. AMF Tjanstepension AB now owns 952,950 shares of the medical equipment provider’s stock valued at $90,864,000 after purchasing an additional 46,538 shares during the last quarter. Capstone Capital Management Ltd bought a new position in shares of Boston Scientific in the 4th quarter valued at about $581,000. Profund Advisors LLC boosted its stake in shares of Boston Scientific by 21.9% in the 4th quarter. Profund Advisors LLC now owns 25,269 shares of the medical equipment provider’s stock valued at $2,409,000 after purchasing an additional 4,542 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of Boston Scientific by 9.3% in the 4th quarter. ProShare Advisors LLC now owns 306,169 shares of the medical equipment provider’s stock valued at $29,193,000 after purchasing an additional 26,021 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. boosted its stake in shares of Boston Scientific by 45.7% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 97,155 shares of the medical equipment provider’s stock valued at $9,256,000 after purchasing an additional 30,469 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Morgan Stanley reduced their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. The Goldman Sachs Group reduced their target price on shares of Boston Scientific from $87.00 to $84.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Canaccord Genuity Group reduced their target price on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating on the stock in a research note on Thursday, April 23rd. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a research note on Thursday, April 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $77.00 target price on shares of Boston Scientific in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $92.83.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific launched a $2 billion accelerated share repurchase, which should reduce share count and support earnings per share. The move signals management confidence and adds a near-term catalyst for the stock. Boston Scientific enters into $2 billion accelerated share repurchase agreement
• Positive Sentiment: The company also announced a $1.5 billion strategic investment in MiRus, taking an approximately 34% stake and gaining an exclusive option to buy MiRus’ TAVR business. Investors view this as a way for Boston Scientific to expand into the fast-growing structural heart market. Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business
• Positive Sentiment: Several analysts reiterated bullish views, including Needham and BTIG, both of which kept buy ratings and highlighted upside potential in BSX shares. Analyst rating updates
• Neutral Sentiment: Boston Scientific was also mentioned on a list of top analyst picks for the week, reflecting continued positive sentiment around the name. 3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22
• Negative Sentiment: One notable offset is that Bank of America lowered its price target on BSX, even while keeping a buy rating, suggesting some caution about valuation or near-term expectations. Bank of America price target update

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $55.86 on Tuesday. The company has a market capitalization of $83.02 billion, a price-to-earnings ratio of 23.37, a P/E/G ratio of 0.97 and a beta of 0.62. The firm’s 50 day simple moving average is $63.06 and its 200 day simple moving average is $81.33. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a fifty-two week low of $52.52 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period last year, the company posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.